Can kidney stones cause fatty liver? This question arises because both conditions are increasingly common in the UK, affecting millions of people. Kidney stones are hard mineral deposits forming in the urinary tract, whilst fatty liver disease involves excessive fat accumulation in liver cells. Although these conditions affect different organ systems, research shows they frequently occur together in the same individuals. This association reflects shared underlying metabolic disturbances rather than one condition directly causing the other. Understanding the relationship between kidney stones and fatty liver is important for comprehensive health management and may inform preventative strategies for those at risk.

Understanding Kidney Stones and Fatty Liver Disease

Kidney stones (renal calculi) are hard mineral deposits that form within the kidneys when substances such as calcium, oxalate, and uric acid become concentrated in the urine. These crystalline structures can range from tiny grains to larger stones several centimetres in diameter. Common symptoms include severe flank or loin-to-groin pain (renal colic), haematuria (blood in urine), nausea, and vomiting. Urinary frequency may occur if a stone reaches the bladder or causes irritation. According to NHS data, kidney stones affect around 1 in 10 people in the UK at some point in their lives, with recurrence rates of approximately 50% within ten years.

Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of liver conditions characterised by excessive fat accumulation in hepatocytes (liver cells) in individuals who consume little to no alcohol. NAFLD ranges from simple steatosis (fat accumulation without inflammation) to non-alcoholic steatohepatitis (NASH), which involves inflammation and potential progression to fibrosis, cirrhosis, or hepatocellular carcinoma. Recent international guidance increasingly uses the term metabolic dysfunction-associated steatotic liver disease (MASLD), though UK NICE guidance currently retains the term NAFLD. NAFLD is increasingly prevalent in the UK, affecting an estimated 20–30% of the general population, with higher rates among those with obesity, type 2 diabetes, and metabolic syndrome.

Both conditions represent significant public health concerns and are associated with considerable morbidity. Whilst kidney stones primarily affect the urinary tract and fatty liver disease affects hepatic function, emerging research suggests these seemingly unrelated conditions may share common underlying metabolic disturbances. Understanding the relationship between kidney stones and fatty liver disease is important for comprehensive patient management and may inform preventative strategies for individuals at risk of either condition.

Can Kidney Stones Cause Fatty Liver?

There is no established causal link between kidney stones and fatty liver disease. These are distinct pathological processes affecting different organ systems—the urinary tract and the liver respectively—with separate primary mechanisms. Kidney stones form through crystallisation processes in the urinary system, whilst fatty liver develops through hepatic lipid accumulation driven by metabolic dysfunction. No proven biological pathway exists whereby the presence of kidney stones would trigger fat deposition in the liver.

However, the relationship between these conditions is more nuanced than simple causation. Epidemiological studies have identified a significant association between kidney stone disease and NAFLD, suggesting they frequently co-exist in the same individuals. Research published in metabolic and nephrology journals indicates that patients with NAFLD have a higher prevalence of kidney stones compared to those without liver disease, and conversely, individuals with recurrent kidney stones show increased rates of fatty liver. This association reflects shared underlying metabolic risk factors rather than one condition causing the other.

This co-occurrence does not imply causation in either direction. Instead, it reflects shared underlying risk factors and metabolic disturbances that predispose individuals to both conditions simultaneously. The association is particularly notable in patients with metabolic syndrome, insulin resistance, and obesity. Understanding this relationship is clinically relevant because patients presenting with one condition may benefit from assessment of metabolic health and management of shared risk factors.

From a clinical perspective, if you have been diagnosed with kidney stones, this does not mean you will develop fatty liver disease, nor does it indicate that the stones have damaged your liver. Similarly, having fatty liver does not directly cause kidney stone formation. The connection lies in the metabolic environment that may promote both conditions independently. NICE does not recommend routine screening for NAFLD in at-risk populations without other clinical indications, but your GP may assess your overall metabolic health if you have either condition alongside other risk factors.

Shared Risk Factors Between Kidney Stones and Fatty Liver

Several modifiable and non-modifiable risk factors are common to both kidney stone formation and fatty liver disease, explaining their frequent co-existence:

Obesity and excess body weight represent perhaps the most significant shared risk factor. Adipose tissue, particularly visceral fat, produces inflammatory cytokines and alters metabolic homeostasis. In the context of kidney stones, obesity increases urinary excretion of calcium, oxalate, and uric acid whilst decreasing urinary pH, creating conditions favourable for stone formation. Simultaneously, obesity drives hepatic fat accumulation through increased free fatty acid delivery to the liver and impaired lipid metabolism.

Insulin resistance and type 2 diabetes profoundly affect both conditions. Insulin resistance alters renal tubular function, reducing urinary pH and citrate excretion (citrate normally inhibits stone formation) whilst increasing calcium excretion. In the liver, insulin resistance promotes de novo lipogenesis (new fat synthesis) and impairs fat oxidation, leading to hepatic steatosis. Studies indicate that individuals with diabetes have a higher risk of developing kidney stones.

Dietary factors play crucial roles in both conditions. Diets high in refined carbohydrates, saturated fats, and animal protein whilst low in fruits and vegetables contribute to both NAFLD and nephrolithiasis. Excessive fructose consumption, in particular, has been implicated in both conditions—promoting hepatic fat accumulation and increasing uric acid production, which can lead to uric acid stones. For kidney stone prevention, NICE guidance (NG118) recommends increasing fluid intake to achieve a urine output of at least 2–2.5 litres per day, reducing dietary salt (to less than 6 grams per day), and moderating animal protein intake. Where relevant, reducing dietary oxalate may also be advised.

Physical inactivity independently increases risk for both conditions by promoting weight gain, insulin resistance, and metabolic dysfunction. Regular physical activity, as recommended by the UK Chief Medical Officers' Physical Activity Guidelines, helps maintain healthy weight and improves metabolic parameters relevant to both kidney and liver health. Adults should aim for at least 150 minutes of moderate-intensity activity per week.

Metabolic Syndrome: The Common Link

Metabolic syndrome serves as the crucial mechanistic link explaining the association between kidney stones and fatty liver disease. This cluster of conditions is typically defined by the presence of at least three of the following: central obesity, elevated blood pressure, raised triglycerides, reduced HDL cholesterol, and elevated fasting glucose. (Note that diagnostic criteria vary slightly between international definitions, including NCEP ATP III and IDF criteria.) Metabolic syndrome creates a metabolic environment that simultaneously promotes both hepatic steatosis and nephrolithiasis.

The pathophysiology involves multiple interconnected mechanisms. Insulin resistance, the hallmark of metabolic syndrome, affects renal tubular handling of various substances. It reduces urinary citrate excretion and pH whilst increasing calcium, oxalate, and uric acid excretion—all changes that favour stone formation. Concurrently, insulin resistance drives hepatic de novo lipogenesis through activation of sterol regulatory element-binding protein-1c (SREBP-1c) and carbohydrate-responsive element-binding protein (ChREBP), leading to triglyceride accumulation in hepatocytes.

Chronic low-grade inflammation, characteristic of metabolic syndrome, affects both organs. Inflammatory cytokines such as tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) contribute to hepatic insulin resistance and steatosis whilst also affecting renal tubular function. Additionally, oxidative stress—elevated in metabolic syndrome—promotes both liver injury in NAFLD and crystal formation in the urinary tract.

Recognising metabolic syndrome as the common denominator has important clinical implications. Patients diagnosed with either kidney stones or fatty liver disease should be assessed for metabolic syndrome components. NICE guidance (NG49) recommends that patients with NAFLD undergo assessment for cardiovascular risk factors, including blood pressure, lipid profile, and screening for type 2 diabetes. Similar metabolic assessment is increasingly recognised as good clinical practice in recurrent stone formers. Addressing metabolic syndrome through lifestyle modification—including weight loss, dietary changes, and increased physical activity—may simultaneously reduce risk for both conditions and improve overall cardiometabolic health.

When to Seek Medical Advice for Both Conditions

For kidney stones, seek immediate medical attention (A&E or call 999) if you experience:

• Severe, persistent flank or abdominal pain that doesn't improve with over-the-counter analgesia

• Pain accompanied by fever, chills, or rigors (suggesting possible infection, which is a medical emergency if the urinary tract is obstructed)

• Visible blood in urine with pain

• Inability to pass urine or significantly reduced urine output

• Persistent nausea and vomiting preventing oral intake

These symptoms may indicate complications requiring urgent assessment. Imaging is typically arranged in hospital: non-contrast CT of the kidneys, ureters, and bladder (CT KUB) is the gold-standard investigation in most adults, though ultrasound is preferred first-line in pregnancy and in children (NICE NG118). If you have recurrent kidney stones (two or more episodes), your GP should arrange initial blood tests (including urea and electrolytes, calcium, bicarbonate, and uric acid; parathyroid hormone if calcium is elevated) and refer you to urology or a metabolic stone clinic for specialist evaluation, which may include 24-hour urine collection to identify underlying metabolic abnormalities.

For fatty liver disease, most cases are asymptomatic and detected incidentally through abnormal liver function tests or imaging. However, consult your GP if you experience:

• Persistent fatigue or malaise

• Discomfort or fullness in the right upper abdomen

• Unexplained weight loss

• Jaundice (yellowing of skin or eyes)

• Easy bruising or bleeding

It is important to note that liver function tests (LFTs) can be normal in NAFLD and do not reliably indicate the severity of liver disease. NICE guidance (NG49 and DG34) recommends that patients with NAFLD undergo assessment of fibrosis risk using non-invasive scores such as the FIB-4 or NAFLD fibrosis score, with age-appropriate cut-offs. If these scores are indeterminate or suggest high risk, the Enhanced Liver Fibrosis (ELF) blood test should be arranged, and referral to hepatology may be indicated. Patients with NAFLD should also be assessed for cardiovascular risk factors and screened for type 2 diabetes.

If you have been diagnosed with either condition, discuss with your GP whether assessment of your overall metabolic health would be appropriate. This is particularly important if you have additional risk factors such as obesity, diabetes, hypertension, or dyslipidaemia. A comprehensive metabolic assessment allows for targeted interventions that may benefit both conditions simultaneously, including structured weight management programmes, dietary modification (including increased fluid intake and salt reduction for stone prevention), increased physical activity, and treatment of underlying metabolic abnormalities. Your GP can coordinate appropriate investigations and refer to specialist services (hepatology, nephrology, urology, or endocrinology) when indicated.

Frequently Asked Questions